JMJD6 and breast cancer: Jumonji domain-containing protein 6 is necessary for both the stable interaction of MED12 with CARM1 (70) and for ERα-dependent BC cell growth and tumorigenesis, indicating that CARM1 inhibitors would be efficacious in the treatment of ERα-positive and endocrine-therapy-resistant BC (70).